Alimera Sciences (NASDAQ:ALIM) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a hold rating to a buy rating in a research note issued to investors on Monday.

Separately, Maxim Group initiated coverage on shares of Alimera Sciences in a research report on Monday, March 25th. They set a buy rating and a $10.00 target price for the company.

Alimera Sciences Trading Up 6.0 %

NASDAQ:ALIM opened at $3.54 on Monday. Alimera Sciences has a 52 week low of $1.56 and a 52 week high of $4.38. The firm has a 50 day moving average of $3.71 and a 200 day moving average of $3.62. The company has a quick ratio of 2.31, a current ratio of 2.39 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $185.32 million, a price-to-earnings ratio of -1.64 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The firm had revenue of $26.31 million for the quarter, compared to analysts’ expectations of $25.10 million. During the same period in the previous year, the company earned ($0.54) EPS. As a group, sell-side analysts anticipate that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Stonepine Capital Management LLC increased its stake in Alimera Sciences by 0.4% during the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after purchasing an additional 15,773 shares in the last quarter. AIGH Capital Management LLC acquired a new position in Alimera Sciences during the 3rd quarter valued at approximately $7,355,000. Finally, Worth Venture Partners LLC acquired a new position in Alimera Sciences during the 3rd quarter valued at approximately $1,840,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).